Targovax

Please note: The information displayed on this page might be outdated.
Targovax: Lead product ONCOS-102 directed to the $25 billion market for checkpoint inhibitors. Targovax is entering late stage development with class-leading clinical data: 1) Entering registrational directed trial in aPD1 refractory melanoma with 35% ORR; 2) Promising survival data in mesothelioma and Fast Track Designation; 3) Clinical and immune data in >200 patients as monotherapy, plus in combo with chemo and CPIs. Targovax has also shown powerful immune activation supporting IO combinations and has a pipeline with multiple additional value creating opportunities.

Oncolytic adenovirus armed with immune stimulating transgene targeting basket of I-O indications. impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
Sector/Industry:
Industrials/Conglomerates
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Finance
Pre-earnings
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Platform Technology, Vaccine
Website:
Profiles:
Address:
Vollsveien 19
Lysaker, Oslo NO-1366
Norway

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Øystein Soug
Targovax, CEO
20 years in international banking and industry, the last six of which as CFO of Algeta ASA and was the former CFO of Targovax ASA. Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014. Prior to joining Algeta in 2008 Mr. Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division. Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. Mr. Soug received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997.

Top 10 Holders of Targovax ASA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Nordea Investment Management AB (Norway) 4.94 4,278,925 0.00 Stakes 10/26/20
Fjärde AP-fonden 4.62 4,000,000 0.00 Stakes 10/26/20
Arctic Fund Management AS (Sweden) 1.70 1,290,959 0.00 Funds 2/26/21
MP Pensjon PK 1.40 1,207,770 0.00 Stakes 10/26/20
Storebrand Asset Management AS 0.39 295,000 0.00 Funds 3/31/21
Handelsbanken Fonder AB 0.23 172,431 0.00 Funds 3/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.